Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond

• Príomhchruthaitheoirí: Xin Li (Údar), Yongping Lin (Údar), Song Lin (Údar), Jiayi Huang (Údar), Zhongbao Ruan (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2024-08-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) are a class of oral targeted anticancer drugs that have been demonstrated to significantly inhibit tumor progression and improve clinical prognosis in patients diagnosed with EGFR-mutated tumors, particularly in those with non-s...